Abstract

The present disclosure provides a method for determining a bacterial concentration in a sample, the method comprising the steps of: (a) introducing (i) a target droplet comprising the sample and (ii) a reference droplet comprising a control medium into an input region of a microfluidic device, the input region comprising a first input channel and a second input channel, wherein the target droplet is introduced into a carrier fluid in the first input channel and the reference droplet is introduced into the carrier fluid in the second input channel; (b) flowing the target and reference droplets from the input region into a synchronisation region to synchronise a pairing of the target and reference droplets; (c) flowing the target and reference droplets from the synchronisation region into a detection region to obtain a raw impedance signal for the pair of target and reference droplets; (d) calculating a calibrated impedance value by dividing a peak impedance value of the raw impedance signal corresponding to the target droplet with a peak impedance value of the raw impedance signal corresponding to the reference droplet; and (e) determining the bacterial concentration from the calibrated impedance value.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

The present invention relates to the use of mitoxantrone hydrochloride as a therapeutic drug for the treatment of neurodegenerative disorder in a subject, wherein the mitoxantrone hydrochloride is an inhibitor of β-amyloid precursor protein (APP) and leucine-rich repeat kinase 2 (LRRK2), capable of inhibiting APP and LRRK2 protein levels in the subject.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

An IL-11 binding receptor capable of binding to IL-11 and inhibiting IL-11 mediated signalling is disclosed. Also disclosed are compositions comprising the IL-11 binding receptor and methods using the IL-11 binding receptor.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

This invention describes manufacturing of an implant that is customised to a user. Specifically, the invention provides a low-cost manufacturing process for voice prosthesis production. The manufacturing process is modular, allows for manual moulding and includes an intelligent cyber-physical system (iCPS) to optimise cost and the manufacturing process steps.

IPC Classes  ?

• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling

Abstract

The present invention is directed to a method using heat denaturation of DNA fragments having low GC content to enrich for CpG regions that can be enriched by adapter-ligation, subjected to bisulfite conversion, sequenced and analysed, for example, to detect cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using as an immunogen a peptide or polypeptide comprising: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration. Also provided are antibodies produced by such methods, and uses thereof.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

A method for the prognosis of response to treatment for a patient suffering from cancer, the method comprising: measuring the expression of at least one immune marker in a leukocyte sample taken from the patient with cancer; classifying the patient sample into (i) sustainable responders (SR) to selective internal radiation therapy (SIRT) or (ii) transient/non-responders (TR/NR) to (SIRT) based on expression of the at least one immune marker in relation to a predetermined value and treating sustainable responders (SR) to SIRT or SIRT or a composition comprising SIRT and an immunotherapy. In a preferred embodiment, the method is for the prognosis of response to treatment of a Hepatocellular carcinoma (HCC) patient comprising detecting the co-expression of PD-1 or Tim-3 with CCR5; or expression of PD-1, Tim-3, CXCR6, or combinations thereof in a leukocyte sample taken from the patient.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes

Abstract

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to a kit for disrupting binding sites of repressor leukemia/lymphoma-related factor (LRF) of a promotor of a hemoglobin gamma (HbG) locus, compositions comprising said kit, and medical use thereof for treating and preventing β-hemoglobinopathy in a subject, wherein the kit comprising a CRISPR-Cas9 nickase and a pair of guide RNAs (gRNAs), wherein the pair of gRNAs binds to target sequences and results in a disruption of binding sites of repressor LRF in a promotor of HbG locus.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/46 - Hydrolases (3)
• A61P 7/06 - Antianaemics

Abstract

Various embodiments relate generally to an adapter for releasably coupling a drape component to an operating room equipment, and more particularly a drape assembly capable of being suspended from an operating room equipment to form a shield over at least a portion of a table or surface a procedure is being conducted upon.

IPC Classes  ?

• A61B 46/10 - Surgical drapes specially adapted for instruments
• A61B 46/23 - Surgical drapes specially adapted for patients with means to retain or hold surgical implements
• A61B 50/20 - Holders specially adapted for surgical or diagnostic appliances or instruments

Abstract

The present invention relates generally to the field of cell-based methods for assaying DDX3 helicase activity. In particular, various embodiments relate to an engineered reporter cell comprising a reporter expression construct capable of interrogating DDX3 helicase activity. Moreover, various embodiments also relate to methods, uses and systems applying the engineered reporter cell.

IPC Classes  ?

• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed herein is a system for analysing arterial calcium. The system identifies calcium lesions, within an organ boundary, from Non-Contrast Computed Tomography (NCCT) images. A feature learning model is then used to generate a set of images based on an origin of each calcium lesion in the NCCT images and orthogonal axes through that origin and to learn, for each image in the set, calcium image features, inferring detection or otherwise of a calcium lesion in the respective image. A feature vector comprising the calcium image features is then formed for each image, and the feature vectors are concatenated to facilitate generation of a prediction for each calcium lesion, of an artery in which the respective calcium lesion is located. Finally, a scorer predicts a calcium score based on the predictions generated from each calcium lesion.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06T 7/10 - SegmentationEdge detection

Abstract

Disclosed herein are systems and methods for extracting, from an image, a centreline for each of one or more vessels of a vasculature, the system comprising memory, and at least one processor, the memory storing instructions that, when executed by the at least one processor, cause the system to receive, at a receiver system, a first mask of a portion of the vasculature, identify seed points in the image, using a shape analysis model, based on a shape of the vasculature in the first mask, generate, using a centreline tracing model, the centreline for each of the one or more vessels by tracing a traced centreline from each seed point, selecting a candidate centreline from the traced centrelines, based on an anatomical feature of the portion of the vasculature, and filtering the candidate centrelines using one or more geometric shape filters to generate the centreline for each vessel. Finally, a centreline for each vessel is provided as an output.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/10 - SegmentationEdge detection
• G06N 3/00 - Computing arrangements based on biological models
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

Disclosed herein is a method of detecting a DDX3Y in a sample using antibodies that bind to DDX3Y. Also disclosed herein is a method of detecting a disease in a subject indicated by the presence of DDX3Y. Further disclosed herein is a method of identifying subjects with poor disease prognosis as indicated by the presence of DDX3Y.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies

Abstract

Disclosed herein are antigen-specific binding domains that specifically bind to DDX3Y. Examples herein include antibodies that bind to DDX3Y and do not cross-react with DDX3X and compositions comprising the same.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The disclosure concerns a capnography filter device comprising an elongated housing 5 having a first end and a second end, the first and second ends each independently comprising a protrusion, and at least one filter housed within the housing; wherein the at least one filter is characterized by a pore size of about 0.2 µm to about 0.5 µm.

IPC Classes  ?

• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
• B01D 29/41 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups Filtering elements therefor with hollow discs side by side on, or around, one or more tubes, e.g. of the leaf type mounted transversely on the tube

Abstract

There is provided a method of determining the likelihood of a recurrence (or a relapse) of a disease/disorder in a subject, the method comprising determining/detecting a presence of at least one onco-fetal cell type in a sample obtained from the subject, wherein the presence of at least one onco-fetal cell type indicates an increased likelihood of a recurrence/relapse of the disease/disorder (or the presence of a recurrence/relapse of the disease/disorder). Also disclosed are methods of treating or preventing recurrence/relapse of a disease or disorder in a subject, methods of selecting a subject suitable for a therapy, and prognostic kits for use in the methods.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents
• C12N 5/095 - Stem cellsProgenitor cells

Abstract

The present disclosure relates to a method and kits for detecting or determining the presence or likelihood of hyperglycemia in a subject. More particularly, the present invention relates to methods and kits for detecting or determining the likelihood of hyperglycemia in a subject based on a set of biomarkers in a breath sample, the biomarkers comprise at least one of cymene, butanol and pentanol.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

Disclosed herein an optical coherence tomography (OCT) system and an image processing method for OCT. The OCT system comprises a computing module configured to: obtain an initial en face image of an eye of a subject; determine from the initial en face image a defective area comprising an artefact, the defective area corresponding to a region of interest of the eye; obtain a replacement en face image of the region of interest of the eye; and replace the defective area in the initial en face image with the replacement en face image to obtain a stitched en face image.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06N 20/00 - Machine learning

Abstract

Antagonists of interleukin 11 (IL-11)-mediated signalling are disclosed. Also disclosed are pharmaceutical compositions, antibodies, antigen binding fragments, antisense oligonucleotides, siRNA molecules, pharmaceutical combinations, and medical uses in methods of treating a disease or condition characterised by glomerular dysfunction.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Herein disclosed is a device operable to perforate a skin, the device comprising: a housing comprising an upper member and a bottom member, wherein the upper member is detachably engaged to the bottom member; an actuation mechanism housed proximal to the upper member; a biasing member operably coupled to the actuation mechanism; one or more striking members; and more than one blades, each of the more than one blades operably coupled to a corresponding striking member of the one or more striking members, wherein the biasing member is operable to have the actuation mechanism activate an actuating member to drive each of the one or more striking members in a manner which renders each of the more than one blades to perforate the skin.

IPC Classes  ?

• A61B 17/32 - Surgical cutting instruments
• A61B 10/02 - Instruments for taking cell samples or for biopsy

Abstract

The present invention relates to modified U1 snRNAs configured to rescue exon skipping in a mutated ABCA4 gene. In one aspect of the present invention, there is provided a modified U1 small nuclear RNA (snRNA) configured to retain exon 40 in a mature mRNA transcript of a mutated ABCA4 gene, the mutated ABCA4 gene comprising a mutation that induces skipping of exon 40, wherein the mutation is located between 3 base pairs upstream and 8 base pairs downstream of a donor splice site of exon 40, wherein the modification comprises replacing a portion of a single-stranded nucleotide sequence of a 5' region of a wild-type U1 snRNA with a single-stranded binding nucleotide sequence capable of hybridizing to a target sequence present on a pre-mRNA transcript of the mutated ABCA4 gene, and wherein the target sequence is located in a region between 13 base pairs upstream and 15 base pairs downstream of the donor splice site of exon 40. In another aspect, there is provided a nucleic acid construct comprising a polynucleotide sequence encoding the modified U1 snRNA as described herein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/00 - Drugs for disorders of the senses

Abstract

The present disclosure relates to the pharmaceutical field. Specifically, the present disclosure relates to a novel Lipocalin-type prostaglandin D synthase (L-PGDS) mutant (RA L-PGDS) as well as its use in the treatment of amyloid-related diseases.

IPC Classes  ?

• C12N 9/90 - Isomerases (5.)
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Disclosed herein is a method for training a system to segment a computerized tomography (CT) image, comprising receiving a plurality of data groups, each group comprising an image pair comprising a CT image, a magnetic resonance (MR) image and a segmentation mask for the MR image; training a first generator of a first generative adversarial network (GAN) using the image pairs, to generate a synthetic MR image from a CT image based on relationships between image features of the CT image and MR image in each image pair; and training a second generator of a second GAN to generate a synthetic mask for the synthetic MR image based on relationships between features of the synthetic MR image and segmentation mask of each data group.

IPC Classes  ?

• G06T 7/11 - Region-based segmentation
• G06T 7/00 - Image analysis
• G06T 7/174 - SegmentationEdge detection involving the use of two or more images

Abstract

Systems and methods for quantifying circulating tumour DNA (ctDNA) in a plasma sample by performing fragment length analysis of the sequencing data using a ctDNA quantification model to estimate a ctDNA metric of the blood plasma sample. Wherein the ctDNA quantification model comprises a neural network based system trained using a training dataset generated using control cfDNA data augmented with ctDNA data obtained from known cancer samples to generate artificial training dataset records with a known ctDNA metric.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/20 - Supervised data analysis

Abstract

A frailty assessment device including a strength measurement subunit and a movement measurement subunit. The strength measurement subunit including a first grip member, a second grip member, wherein the first grip member and the second grip member are movable relative to each other, and a force sensing arrangement disposed between the first grip member and the second grip member, wherein the force sensing arrangement is configured to measure a force for urging the first grip member and the second grip member towards each other. The movement measurement subunit including a distance sensing arrangement configured to detect a distance of an external body with respect to the device. The strength measurement subunit and the distance measurement subunit are integrated together in a single device body.

IPC Classes  ?

• A61B 5/22 - ErgometryMeasuring muscular strength or the force of a muscular blow
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G01S 17/88 - Lidar systems, specially adapted for specific applications

Abstract

The present invention relates to a composition comprising a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises one or more active agent physically bound to one or more conjugate, wherein each conjugate comprises one or more flavonoid molecule and a first water-soluble polymer, and the nanocomplex is at least partially encapsulated by a second water-soluble polymer. The present invention also relates to a method of preparing the composition and uses thereof. The present invention also relates to a method of treating an eye disease caused by angiogenesis, comprising administering a composition to a subject in need thereof, wherein the composition comprises a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises an ophthalmic anti-angiogenesis drug physically bound to one or more conjugate, each conjugate comprising one or more flavonoid molecule and a first water-soluble polymer.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 27/02 - Ophthalmic agents

Abstract

An endoscopy device and a method of manufacturing an endoscopy device are disclosed. The endoscopy device comprises: a body having a handle portion and a housing portion, the housing portion having an outlet; a switching mechanism disposed in the housing portion; a rigid outer tube detachably coupled to the housing portion at the outlet, and a flexible inner tube extendable from the outer tube, wherein the switching mechanism is configured to retract or extend the inner tube outwardly through the outer tube.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61M 25/00 - CathetersHollow probes

Abstract

The present disclosure generally relates to a computer system and a computerized method for segmenting a medical image of an organ. The method comprises: detecting, using an object detection model, a ROI in the medical image, the ROI comprising a lesion in the organ; demarcating, using the object detection model, a bounding box around the ROI; extracting a localized image comprising the ROI from the medical image, the localized image defined by the bounding box; segmenting, using an image segmentation model that is independent from the object detection model, the localized image comprising the ROI; predicting, using the image segmentation model, a segmentation mask of the lesion in the localized image; and outputting the segmentation mask from the localized image to the medical image to facilitate medical diagnosis of the lesion, wherein the object detection model is trained using a first dataset of training images comprising medical images of the organ, each medical image in the first dataset comprising a ground-truth bounding box for one or more lesions in the organ.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

There is provided an anti-angiogenic agent comprising: a multi-block copolymer in the form of one or more micelles, wherein the copolymer comprises a first poly (alkylene glycol) block, a second poly (alkylene glycol) block and a polyester block. There is also provided a method of preparing said anti-angiogenic agent and medical uses of said anti-angiogenic agent.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 27/02 - Ophthalmic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed herein is a method for determining whether a subject is suffering from, or is at risk of developing breast cancer, wherein the method comprises detecting differential expression levels of at least two or more miRNA markers from a biological sample. Also disclosed herein is a method of determining whether a subject is suffering from, or is at risk of developing, breast cancer based on miRNA expression.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

This technology relates to a method of treating a liver cancer, and a method of predicting a response of a subject suffering from liver cancer to a treatment with an immune checkpoint inhibitor. This technology further relates to a method of predicting a treatment-induced immune-related adverse events (irAEs) of a subject suffering from liver cancer to a treatment with an immune checkpoint inhibitor.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6869 - Methods for sequencing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to an RNA-responsive transducer, the transducer comprising a catalytic nanoparticle complex linked to a magnetic bead via a single- stranded DNA probe specific for a target RNA, wherein the single-stranded DNA probe will form a duplex with the target RNA, and wherein in the presence of a duplex-specific nuclease, which recognizes an RNA-DNA duplex, the DNA linker is cleaved thereby: i) liberating the catalytic nanoparticle complex, and ii) releasing the target RNA to form a DNA-RNA duplex with another RNA-responsive transducer. The invention also relates to methods of use of the transducer and catalytic enzyme to detect RNA, with a microfluidic device to enable digital quantification, diagnosis and subtyping.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes
• C07F 3/06 - Zinc compounds
• C12N 11/04 - Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present disclosure generally relates to a system and computerized method (200) for monitoring physiology of a user using photoplethysmography (PPG) signals (310). The method (200) comprises: receiving (210) a set of PPG signals (310), each PPG signal measured from a different location on the user; identifying a plurality of 2D pulse wavelets (312) from each PPG signal (310); aligning the respective 2D pulse wavelets (312) in 3D; and constructing a set of 3D morphological representations (400) from the aligned pulse wavelets (312), wherein a set of physiological parameters (410) of the user is measurable based on the constructed 3D morphological representations (400).

IPC Classes  ?

• A61B 5/021 - Measuring pressure in heart or blood vessels
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A method includes determining a first change from a first FTIR spectrum of bare SEIRA structures to a second FTIR spectrum of SEIRA structures bound with complementary molecules; determining a second change from the second FTIR spectrum to a third FTIR spectrum of SEIRA structures bound with the complementary molecules and the target molecules; and determining a presence and/or a concentration of the target molecule. The method may include determining an area ratio indicative of a concentration of the target molecule. A device includes a plurality of wells to receive an amount of the sample. Each well is isolated from any other of the plurality of wells. A SEIRA sensor is disposed in each well, in which the SEIRA sensor is configured with a resonant response in a plurality of resonant peak frequencies distributed over a range of frequencies.

IPC Classes  ?

• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light

Abstract

There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

coco-glycolic acid) (PLGA) copolymer; and (iii) pores patterned on said material. Also provided are a medical device comprising said regenerative material, medical uses of said regenerative material, and a method of preparing said regenerative material.

IPC Classes  ?

• A61L 15/24 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent L is a linker unit, —is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

There is provided an antibacterial composition comprising: nanostructures of a Group (II) metal oxide-hydroxide composite. There is also provided a method of forming the antibacterial composition. In a particular embodiment, the Group (II) metal oxide-hydroxide composite may be magnesium oxide-hydroxide composite, calcium oxide-hydroxide composite, or a combination thereof.

IPC Classes  ?

• A01N 25/24 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
• C01F 5/16 - Magnesium hydroxide by treating magnesia, e.g. calcined dolomite, with water or solutions of salts not containing magnesium
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The invention relates to a sensor glove for monitoring scratching activity, comprising a glove portion having a plurality of finger portions; a plurality of stretch sensors arranged over the finger portions; an inertial measurement unit configured to measure acceleration of a hand of a wearer of the sensor glove; and a controller unit coupled to the stretch sensors configured to receive signals from the stretch sensors. A machine learning method of identifying scratching activity in a subject using finger bending data from the stretch sensors and hand inertial data from the inertial measurement unit, a computer readable medium and a data processing device thereof, and a system comprising the sensor glove and the data processing device are also provided.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

A method of training a machine learning model for classifying a temporal phase signal obtained from OCT images produced for optoretinography is provided. The method includes: obtaining a series of OCT images produced by a phase-sensitive OCT system for optoretinography with respect to an outer retina, including a stimulus sub-series of OCT images produced in response to a visual stimulus to the outer retina; determining, for each OCT image of the series of OCT images and for each of a plurality of individual pixels in a target layer of the OCT image, a phase signal of the individual pixel in the target layer of the OCT image with respect to a reference layer of the OCT image to obtain, for each series of corresponding individual pixels of a plurality of series of corresponding individual pixels in the target layer across the series of OCT images, a temporal phase signal of the series of corresponding individual pixels, resulting in a set of temporal phase signals for the plurality of series of corresponding individual pixels, the target layer comprising a plurality of outer retinal bands; projecting a plurality of temporal phase signals of the set of temporal phase signals to a plurality of feature points in a feature space; labelling each of the plurality of feature points in the feature space; and training the machine learning model based on the plurality of labelled feature points in the feature space. There is also provided a method of classifying a temporal phase signal obtained from OCT images produced for optoretinography using the trained machine learning model.

IPC Classes  ?

• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• G06T 7/00 - Image analysis

Abstract

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof which binding to CEACAM6, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH; a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG; and a VHCDR3 having the amino acid sequence STARATPYFYAMDY and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS, a VLCDR2 having the amino acid sequence GASIRES, and a VLCDR3 having the amino acid sequence QHNHGSFLPYT. The present invention also relates to compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof for cancer treatment, prevention or detection and a kit comprising the antigen-binding protein, or antigen-binding fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a chimeric antigen receptor (CAR) comprising an extracellular domain that binds to one or more inflammation associated factor(s), a transmembrane/hinge domain and an intracellular domain. In a specific embodiment, a T regulatory (Treg) cell expressing a construct encoding said CAR which further comprising a Fox3p and a CAR activation-dependent NF-AT promoter that drives the expression of interleukin-10 and TGF-beta. It also relate to the methods of producing the CAR, the Treg cells expressing said CAR and the use of said CAR to treat autoimmune diseases such as transplant rejection, a graft versus host disease (GVHD) and cytokine release syndrome..

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

A method for measuring urine osmolality comprises: receiving a urine sample; mixing 5 an adsorbent with the urine sample, resulting in a urine-adsorbent mixture; determining an electrical impedance of the urine sample; measuring a refractive index of the urine-adsorbent mixture; determining an osmolality of the urine sample using both the electrical impedance of the urine sample and the refractive index of the urine- adsorbent mixture.

IPC Classes  ?

• G01N 33/493 - Physical analysis of biological material of liquid biological material urine
• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• C01B 32/30 - Active carbon

Abstract

There is provided a method and a system for generating treatment regimens for a medical condition for a subject in need thereof, the method comprising, parsing pre-processed data of the subject through an optimizer to obtain a list of feasible treatment regimens; parsing a selected subset of the list of feasible treatment regimens through a trained artificial intelligence (AI) model to obtain predicted clinical outcomes for each of the selected subset of the list of feasible treatment regimens; obtaining an associated cost for each of the selected subset treatment regimens; obtaining an associated preference score for each of the selected subset of treatment regimens; generating an associated value score for each of the selected subset of treatment regimens, said associated value score based on the predicted clinical outcomes, associated costs, and associated preference score of the selected subset of the list of feasible treatment regimens; and generating one or more recommended treatment regimens based on the associated value scores, each recommended treatment regimen comprising a drug mix and dose regimen.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to the maintenance and/or culture of tissue slices in vitro or ex vivo. In particular, the present invention relates to a method for the maintenance and/or culture of tissue slices using hydrogels. In one embodiment, the hydrogel is a semi-synthetic hydrogel comprising thiolated hyaluronan with acrylated peptides comprising KGGGPQGIWGQGK (SEQ ID NO: 1) that are degradable by matrix metalloproteinases. In particular, the present invention provides a platform suitable for downstream analysis such as real-time imaging, other real-time study of the tissue in culture and testing of a therapeutic agent or a potential therapeutic agent.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/09 - Tumour cells

Abstract

Disclosed are anti-transient receptor potential melastatin 4 (TRPM4) antibodies and their use for treating traumatic brain injury and vascular dementia. In particular, disclosed are humanized monoclonal antibodies specific to TRPM4 and their use for treating traumatic brain injury and vascular dementia.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed are anti-transient receptor potential melastatin 4 (TRPM4) antibodies and their use for treating cytokine-associated vascular diseases. In particular, disclosed are humanized monoclonal antibodies specific to TRPM4 and their use for treating cytokine- associated vascular diseases, including cytokine-associated pulmonary injury and cytokine-associated pulmonary vascular damage.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Disclosed is a system for delivering a commode to a patient. The system includes a transceiver system, a commode delivery robot and a commode (or multiple commodes). In use, the system receives, at the transceiver system, a commode request, and in response to the commode request the commode delivery robot delivers the commode to the patient. The system also receives, at the transceiver system, a completion request, and in response to the completion request the commode delivery robot delivers the commode to a disposal location.

IPC Classes  ?

• A47K 11/04 - Room closetsChairs with toilet conveniences or specially adapted for use with toilets, e.g. night chairs
• A47K 11/06 - Chamber-pots
• A47K 11/08 - Night cabinets or tables with closets or bidet equipment
• A61G 7/02 - Beds specially adapted for nursingDevices for lifting patients or disabled persons with toilet conveniences, or specially adapted for use with, toilets
• A61G 9/00 - Bed-pans, urinals or other sanitary devices for bed-ridden personsCleaning devices therefor, e.g. combined with toilet-urinals

Abstract

Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The disclosure concerns radioluminescent films, systems and their uses thereof. The radioluminescent system comprises an imaging chamber comprising a camera and/or photodetector housed within the imaging chamber; and a control system operable to activate the camera and/or photodetector; wherein a radioluminescent film configured to exhibit persistent radio-luminescence upon excitation by an ionizing radiation is positionable within the imaging chamber for quantifying and/or spatially mapping the persistent radio-luminescence of the radioluminescent film by the camera and/or photodetector; wherein the radioluminescent film comprises a plurality of scintillator crystals dispersed on a surface of a polymer layer or within the polymer layer.

IPC Classes  ?

• G21K 4/00 - Conversion screens for the conversion of the spatial distribution of particles or ionising radiation into visible images, e.g. fluoroscopic screens
• G01T 1/115 - Read-out devices
• A61B 6/58 - Testing, adjusting or calibrating thereof
• C09K 11/85 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals containing halogen
• C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead

Abstract

A connector for a fluidic circuit and a method for assembling the connector are disclosed. The connector includes a valve body having at least three ports comprising first and second inlet ports and an outlet port; and a valve switch attached to the valve body, the valve switch being movable between a plurality of positions relative to the valve body; wherein, in a first position, the valve switch is configured to fluidically connect the first inlet port to the outlet port, and fluidically seal the second inlet port from the outlet port; and wherein, in a second position, the valve switch is configured to fluidically connect the second inlet port to the outlet port, and fluidically seal the first inlet port from the outlet port.

IPC Classes  ?

• A62B 9/04 - CouplingsSupporting frames
• A62B 9/02 - Valves

Abstract

Methods of treating and preventing metabolic disease through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 3/00 - Drugs for disorders of the metabolism
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition or IL-11-mediated signalling.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 35/00 - Antineoplastic agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates, in general terms, to cancer biomarkers. Disclosed herein are methods of identifying cancers that are suitable for NF-κB inhibition therapy, and methods of selecting subjects for the same, comprising detecting an indicator that is indicative of a level or activity of Protein polybromo-1 (PB1) in a sample obtained from the subject, wherein the cancer is identified as being likely to be responsive to the inhibitor of NF-κB signalling when the level or activity of PB1 indicated by the indicator corresponds to an absence or decreased level or activity of PB1 in the sample as compared to a control.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/69 - Boron compounds
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a system of detecting vasculature in optical coherence tomography (OCT) image data of a tissue of a subject, the OCT image data comprising OCT scan data and OCT angiography (OCTA) scan data, the system comprises segmenting the OCT scan data to locate a layer of interest in the tissue; generating an en face vascular network map from the OCTA scan data; projecting one or more vascular regions from the en face vascular network map onto the layer of interest in a cross-sectional image of the OCT scan data to define one or more regions of interest (ROIs), wherein respective ROIs are defined by the intersection between the vascular regions and the layer of interest; and identifying vascular objects in the one or more ROIs. In the preferred embodiment, the tissue is retina, vessels are removed from the layer of interest and the retinal nerve fibre layer (RNFL) thickness is determined.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A bracket, a system, and a method of inspection and assembly of surgical instrument sets using the bracket are disclosed. The method includes: using a first robotic arm to perform transferring of a plurality of ring instruments together before and/or after a ring instrument inspection, the first robotic arm being controllably operable to pick up and transfer a bracket; disengaging each one of the plurality of ring instruments in turn from the bracket before the ring instrument inspection; performing the ring instrument inspection of the plurality of ring instruments one ring instrument at a time in turn, with the one ring instrument disengaged from the bracket; and assembling the bracket with a predefined number of predefined types of the ring instruments in a predefined order.

IPC Classes  ?

• A61B 50/20 - Holders specially adapted for surgical or diagnostic appliances or instruments
• A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
• A61L 2/24 - Apparatus using programmed or automatic operation
• G01N 1/36 - Embedding or analogous mounting of samples
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation

Abstract

A needle guiding system is described. The needle guiding system comprises a marking device 402, the marking device 402 comprising: a base 602; an angle scale 604 having angle markings indicating angle positions of an imaging probe with respect to a plane of the base 602; and an angle indicator 606 adapted to indicate a probe angle on the angle scale 604, wherein the angle indicator 606 is configured to move in tandem with the imaging probe to identify an insertion angle for needle insertion when the imaging probe is aligned at the insertion angle at an insertion site. A needle guide 404 and a method for using the needle guiding system in guiding a needle for needle insertion of a patient are also described.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles

Abstract

The invention relates to methods of increasing sensitivity of an epidermal growth factor receptor (EGFR)-related cancer to EGFR tyrosine kinase inhibitor (TKI) comprising administering a therapeutically effective amount of EGFR isoform D to a subject in need thereof. The invention also relates to methods of treating a subject suffering from an EGFR-related cancer comprising administering to the subject an effective amount of EGFR isoform D and a TKI. In one embodiment, the EGFR-related cancer is head and neck squamous cell carcinoma (HNSCC).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

There are provided a composition and a method of preparing the composition. The composition comprises a composite powder material and an elastomer, wherein the composite powder material comprises a) tourmaline particles, b) rare-earth mineral particles, c) silicate mineral particles, d) metal oxide particles, and e) a binder, and wherein the sizes of the a), b), c) and d) are 5 pm or less. There are also provided an article and a method of preparing an article. There are further provided methods of using and uses of the article in the form of catheters, particularly urinary catheters.

IPC Classes  ?

• A61L 29/04 - Macromolecular materials
• A61L 29/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances
• A61M 25/00 - CathetersHollow probes

Abstract

The present disclosure generally relates to an apparatus (100) and method for tracking a device (200) having a magnet (210). The apparatus (100) comprises magnetic sensors (110) arranged longitudinally and configured for measuring a magnetic field from the magnet (210) as the device (200) moves along a trajectory (220). A processor receives the magnetic field measurements of the magnet (210); determines, for each magnetic sensor (110), axial magnetic field components directed along mutually orthogonal axial directions; selects the axial magnetic field components that satisfy a threshold predefined for each axial direction; calculates a pose of the magnet (210) using the selected axial magnetic field components and predetermined magnetic moments for the magnetic sensors (110); and tracks the device (200) using the calculated poses of the magnet (210) as the device (200) moves along the trajectory (220).

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux

Abstract

An implantable prosthesis and delivery' system for treating tricuspid valve regurgitation (TVR). The system is configured for pre-loading into a percutaneous delivery7 system. The system includes a self-expanding anchoring stent with an attached and positionable coaptation member. The stem is implanted in the inferior vena cava proximate the right atrium and is connected to the coaptation member with a. steering tube and a multi-directional coupler and gimbal assembly. The coaptation member is fabricated from a porous or semi-porous material formed over a wire frame and is configured, possibly with leaflet matching curvature, before implantation. When deployed, the coaptation member self-aligns, self-inflates, and takes shape over several cardiac cycles to conform to the patient's TV defects and to provide coaptation surfaces for native leaflets to reduce TVR.

IPC Classes  ?

• A61F 2/24 - Heart valves
• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts

Abstract

An implantable prosthesis and delivery' system for treating tricuspid valve regurgitation. The system is configured for pre-loading into a percutaneous delivery' system and includes a self-expanding anchoring stent with an attached and positionable coaptation member. The stent is implanted in the inferior vena cava proximate the right atrium and is connected to the coaptation member via a multi-directional coupler and gimbal assembly. The coaptation member is fabricated from a porous or semi-porous material formed over a wire frame and is configured, possibly with leaflet matching curvature, before implantation. When deployed, the coaptation member self-aligns, self-inflates, and takes shape over several cardiac cycles to conform to the patient's tricuspid valve defects and to provide coaptation surfaces for native leaflets to reduce TVR.

IPC Classes  ?

• A61F 2/24 - Heart valves
• A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
• A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts

Abstract

The present disclosure relates to the diagnosis, treatment and prophylaxis of age-related diseases, and increasing healthspan. Provided are methods of treating or preventing an age-related disease/condition, and in particular of treating or preventing frailty, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject. Also provided are agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in such a method. Further provided is the use of agents capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in such a method.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The disclosure relates to methods of treatment and methods of identifying subjects for such treatment based on levels of pirin and/or iron in samples from the subject. In one embodiment, the subject is suffering from cancer, such as colorectal cancer, hemochromatosis or anaemia. In one embodiment, the treatment includes administration of iron chelator or pirin inhibitor.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61P 35/00 - Antineoplastic agents

Abstract

A prosthetic implant including an anchor member; at least one resilient tethering strut extending from the anchor member; a coaptation structure coupled to an end of the at least one resilient tethering strut; and a tensioning unit extending between the anchor member and the coaptation structure. The tensioning unit including a flexible hollow tubing, and a tensioning wire extending therethrough with a first end of the tensioning wire fixed at a junction between a first end of the flexible hollow tubing and the coaptation structure and with a second end of the tensioning wire extending out from a second end of the flexible hollow tubing. The second end of the tensioning wire being pullable away from the second end of the flexible hollow tubing to bend the flexible hollow tubing and the at least one resilient tethering strut to move the coaptation structure relative to the anchor member.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

A system for polarization-sensitive optical coherence tomography (PS-OCT) of a sample comprises an interferometric arrangement comprising a reference arm and a sample arm, the sample arm being arranged to emit optical radiation towards the sample; a phase modulation system arranged at an input to the sample arm; and a detector arranged to detect a signal generated by interference between a reference beam from the reference arm and a sample beam from the sample arm. The phase modulation system comprises: an electro-optic modulator; a polarizer arranged at a rotation angle relative to the fast axis of the electro-optic modulator; and a signal generator for delivering a driving voltage to the electro-optic modulator; wherein the rotation angle and the driving voltage are selected such that the phase modulation system generates three mutually orthogonal polarization states.

IPC Classes  ?

• G01N 21/23 - Bi-refringence
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G01N 21/21 - Polarisation-affecting properties
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour

Abstract

Methods and systems for simulating a stent in a coronary artery lumen structure are disclosed. A method of simulating a stent in a coronary artery lumen structure, the method comprises: reconstructing a three-dimensional coronary artery tree from segmented coronary lumen contours; replacing part of the three-dimensional artery tree with a candidate stent structure; and simulating pressure distribution through the coronary artery tree to determine a non-invasive fractional flow reserve through the candidate stent structure.

IPC Classes  ?

• G06T 7/10 - SegmentationEdge detection
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G06T 7/64 - Analysis of geometric attributes of convexity or concavity
• G06T 7/66 - Analysis of geometric attributes of image moments or centre of gravity
• G06V 10/46 - Descriptors for shape, contour or point-related descriptors, e.g. scale invariant feature transform [SIFT] or bags of words [BoW]Salient regional features
• G06T 17/00 - 3D modelling for computer graphics
• G06T 7/00 - Image analysis

Abstract

Disclosed herein a method of treating a BAP1 -related tumour in a subject, the method comprising determining whether BAP1 in the sample is functional or non-functional, and administering to the subject a therapeutically effective amount of a PARP inhibitor and a LSD1 inhibitor if BAP1 in the sample is non-functional. Also disclosed herein is a method screening and identifying an anti-proliferative compound, the method comprising obtaining a population of BAP1-deficient cells, treating said BAP1 -deficient cell population with the anti-proliferative compound, and determining a change in proliferative activity of the population of BAP1 -deficient cells compared to a population of cells producing functional BAP1 protein.

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

This technology relates to a method of treating breast cancer in a subject and a method of determining whether a breast lesion in a subject is malignant or benign using miRNA panels.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure provides apoptosis related protein in the TGF-beta signaling pathway (ARTS) mimetic compounds, compositions and uses thereof for treating neoplastic disorders affecting the neural system and/or neural cell in a subject in need thereof, specifically neuroblastoma. The present disclosure further provides combined compositions of these ARTS mimetic compounds.

IPC Classes  ?

• C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

The invention relates to a method of generating an induced pluripotent stem cell. The method of the disclosure comprises expressing exogenous nucleic acids encoding the proteins OCT3/4, SOX2, KLF4, LIN28 and L-MYC and the p53-shRNA in a stem cell of the amniotic membrane of the umbilical cord under conditions suitable to reprogram the stem cell, thereby generating the induced pluripotent stem cell. The present invention also refer to an induced pluripotent stem cell population obtainable by the method and an induced pluripotent stem cell population obtained by the method. Further, a pharmaceutical composition comprising the induced pluripotent stem cell of the present invention is concerned. The present invention also relates to a method of differentiating the induced pluripotent stem cell of this invention. In addition, a pharmaceutical composition comprising a differentiated induced pluripotent stem cell obtained by the method is also concerned. Further, the present invention concerns a method of treating a congenital or acquired degenerative disorder in a subject, comprising administering to a subject a target cell differentiated from pluripotent stem cell.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• C12N 5/074 - Adult stem cells
• A61P 25/16 - Anti-Parkinson drugs
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present disclosure relates to methods for culturing human epidermal keratinocytes. When keratinocytes are cultured on plates coated with a laminin containing an alpha-4 chain or an alpha-5 chain, in a xeno-free, chemically defined cell culture medium, they expand efficiently in vitro. Useful cell culture kits for culturing keratinocytes are also described herein, as are methods of using such cells for treatment of burns or chronic wounds.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Disclosed herein is a method of segmenting a volumetric image comprising a plurality of slices, the method comprising: inputting a target slice of the volumetric image to a deep neural network (DNN) having a multi-task learning architecture, the multi-task learning architecture comprising: a segmentation DNN that is configured to output a segmentation of the target slice; and a reconstruction DNN that is configured to: receive a plurality of adjacent slices to the target slice; and output a reconstruction of the target slice based on the plurality of adjacent slices; wherein the reconstruction DNN is further configured to share spatial information with the segmentation DNN, the spatial information being indicative of correlations between the adjacent slices and the target slice.

IPC Classes  ?

• G06T 7/11 - Region-based segmentation
• G06T 7/174 - SegmentationEdge detection involving the use of two or more images
• G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
• G06T 7/00 - Image analysis
• G06T 11/00 - 2D [Two Dimensional] image generation
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes

Abstract

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using as an immunogen a peptide or polypeptide comprising: (i) an antigen sequence, comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration. Also provided are antibodies produced by such methods, and uses thereof.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 27/00 - Drugs for disorders of the senses

Abstract

The present invention relates to a method of treating lymphedema comprising administering an effective amount of a composition to a patient in need thereof. The composition consisting essentially of cyclodextrin or a pharmaceutically acceptable salt, solvate or prodrug thereof. The present invention also relates to a composition consisting essentially of cyclodextrin.

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61P 7/10 - Antioedematous agentsDiuretics

Abstract

An isolation chamber includes a plurality of walls and ceiling defining an internal chamber and a first and second door. The doors seal engagement with the walls. A fan filter unit is arranged to extract air from the internal chamber. The isolation chamber is arranged to couple to a doorway, and the coupling arranged to provide an airtight seal about the doorway.

IPC Classes  ?

• F24F 7/06 - Ventilation with ducting systems with forced air circulation, e.g. by fan
• A61G 10/00 - Treatment rooms for medical purposes
• A61L 2/20 - Gaseous substances, e.g. vapours
• A61L 2/26 - Accessories
• E04H 1/12 - Small buildings or other erections for limited occupation, erected in the open air or arranged in buildings, e.g. kiosks, waiting shelters for bus stops or for filling stations, roofs for railway platforms, watchmen's huts or dressing cubicles
• E04H 3/08 - Hospitals, infirmaries, or the likeSchoolsPrisons

Abstract

A liquid flowrate gauge including a receptacle structure having a surrounding wall around a central axis, wherein an outlet port and an inflow opening are disposed on opposite sides of the receptacle structure along the central axis; and a floatable member loosely sitting within the receptacle structure in a manner so as to define at least one gap between the floatable member and the receptacle structure to maintain a flow path therethrough. The outlet port is dimensioned to achieve a liquid flowrate equal to or above a threshold outlet flowrate and the floatable member is configured to be floated when a liquid level of a liquid accumulated in the receptacle structure is equal to or higher than a predetermined height. The floatable member being floated serve as an indication that a rate of inflow of the liquid is equal to or above the threshold outlet flowrate.

IPC Classes  ?

• A61B 5/20 - Measuring urological functions
• G01N 33/493 - Physical analysis of biological material of liquid biological material urine
• G01N 11/04 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by measuring flow of the material through a restricted passage, e.g. tube, aperture

Abstract

Methods of treating and preventing Alport syndrome through inhibiting interleukin 11 (EL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present disclosure describes a radiation sensing and reporting devices, systems, and methods. The devices and systems are a flexible material that detects the presence of radiation over a surface area and reports the specific location and intensity of the radiation. An article is provided that includes a substrate; a plurality of radiation sensors, each radiation sensor of the plurality of radiation sensors being disposed at a corresponding position on the substrate; and alert circuitry coupled to the plurality of radiation sensors, wherein the alert circuitry indicates, in real time, a localized detection of radiation according to corresponding one or more positions on the substrate of a particular one or more radiation sensors of the plurality of radiation sensors.

IPC Classes  ?

• G01T 3/06 - Measuring neutron radiation with scintillation detectors
• G01T 1/172 - Circuit arrangements not adapted to a particular type of detector with coincidence circuit arrangements
• G01T 7/12 - Provision for actuation of an alarm

Abstract

A graphene oxide-based membrane There is provided a graphene oxide-based membrane comprising a substrate and a plurality of layers of single-layered graphene oxide formed on the substrate, each of the plurality of layers of single-layered graphene oxide is functionalised by at least one diamine functional group, wherein interlayer spacing between two adjacent layers of single-layered graphene oxide is ≤ 10 Å. The membrane may be comprised in an electrocapacitive unit. There is also provided a method of forming the membrane.

IPC Classes  ?

• B01D 71/02 - Inorganic material
• C01B 32/198 - Graphene oxide
• C01B 32/194 - After-treatment
• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• B01D 69/10 - Supported membranesMembrane supports
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 61/42 - ElectrodialysisElectro-osmosis

Abstract

Antagonists of interleukin 11 (IL-11)-mediated signalling are disclosed. Also disclosed are pharmaceutical compositions, antibodies, antigen binding fragments, antisense oligonucleotides, siRNA molecules, pharmaceutical combinations, and medical uses in methods of treating a disease or condition characterised by glomerular dysfunction.

IPC Classes  ?

• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Abstract

The present disclosure describes a pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein. Disclosed herein is also the use of said pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases. Further disclosed herein is the use of the pharmaceutical composition for immunomodulation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 38/19 - CytokinesLymphokinesInterferons

Abstract

The present invention relates to compositions comprising an anionic polymer, such as hyaluronate or alginate, a cation such as calcium, an anion such as phosphate, and nucleic acids such as siRNA for the SPARC gene. The compositions are used for delivery of nucleic acids to cells to thereby regulate gene expression and treat diseases such as ocular fibrosis disorders.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61P 27/00 - Drugs for disorders of the senses
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

Disclosed herein is a method for training a system to segment a computerized tomography (CT) image, comprising receiving a plurality of data groups, each group comprising an image pair comprising a CT image, a magnetic resonance (MR) image and a segmentation mask for the MR image; training a first generator of a first generative adversarial network (GAN) using the image pairs, to generate a synthetic MR image from a CT image based on relationships between image features of the CT image and MR image in each image pair; and training a second generator of a second GAN to generate a synthetic mask for the synthetic MR image based on relationships between features of the synthetic MR image and segmentation mask of each data group.

IPC Classes  ?

• G06T 7/174 - SegmentationEdge detection involving the use of two or more images

Abstract

The present invention relates generally to the field of compositions for use in diagnostic methods. In particular, the present invention relates to a composition for use in a diagnostic method wherein the composition is a nutritional composition comprising 15-70 g fat, 60-90 g carbohydrates and 15-35 g protein. The diagnostic method may be a method to predict the risk of atheroma plaque presence in a subject.

IPC Classes  ?

• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/19 - Dairy proteins

Abstract

The present invention relates to a composition comprising a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises one or more active agent physically bound to one or more conjugate, wherein each conjugate comprises one or more flavonoid molecule and a first water-soluble polymer, and the nanocomplex is at least partially encapsulated by a second water-soluble polymer. The present invention also relates to a method of preparing the composition and uses thereof. The present invention also relates to a method of treating an eye disease caused by angiogenesis, comprising administering a composition to a subject in need thereof, wherein the composition comprises a self-assembled nanocomplex, wherein the self-assembled nanocomplex comprises an ophthalmic anti-angiogenesis drug physically bound to one or more conjugate, each conjugate comprising one or more flavonoid molecule and a first water- soluble polymer.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 39/44 - Antibodies bound to carriers
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention refers to a method of identifying whether a subject is at risk of developing PD (PD), whether a subject is suffering from PD, or whether a subject is in need of early therapeutic intervention for PD, the method comprising detecting the presence of a genetic variant at the loci of one or more genes selected from the group consisting of SV2C, WBSCR17, PARK16, ITPKB, MCCC1, SNCA, FAM47E-SCARB2, FYN, DLG2, LRRK2, RIT2 and combinations thereof in a sample obtained from the subject, wherein the presence of one or more genetic variants identifies that the subject is at risk of developing PD, the subject is suffering from PD, or the subject is in need of early therapeutic intervention for PD. Also, described herein are a method of determining the prognosis of a subject with PD or a subject at risk of developing PD and a method for calculating a polygenic risk score (PRS) of a subject of developing PD. Further, described herein are biomarkers and kits for PD.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An endoscopy device and a method of manufacturing an endoscopy device are disclosed. The endoscopy device comprises: a body having a handle portion and a housing portion, the housing portion having an outlet; a switching mechanism disposed in the housing portion; a rigid outer tube detachably coupled to the housing portion at the outlet, and a flexible inner tube extendable from the outer tube, wherein the switching mechanism is configured to retract or extend the inner tube outwardly through the outer tube.

IPC Classes  ?

• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61B 1/233 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the nose, i.e. nasoscopes
• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/005 - Flexible endoscopes

Abstract

The present invention relates to methods of treating or ameliorating seizures relating to disruptions in Ubiquitin Protein Ligase E3A (UBE3A) gene. More particularly, the invention relates to the use of BK channel antagonists for the prophylaxis or treatment of seizures in a subject with Angelman syndrome or related autism spectrum disorder (ASD). In some embodiments, BK channel antagonist is Paxilline, iberiotoxin (IBTX) or GAL-021.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

Disclosed herein is a method for determining whether a subject is suffering from, or is at risk of developing breast cancer, wherein the method comprises detecting differential expression levels of at least two or more miRNA markers from a biological sample, preferably serum. Specifically, miR-133a-3p, miR-497-5p, miR-24-3p, and miR-125b-5p are upregulated, while miR-377-3p, miR-374c-5p, miR-324-5p and miR-19b-3p are downregulated in serum samples from breast cancer cases as compared to non-cancer controls.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

Ultrasound imaging methods for identifying an anatomical feature of a spine are described. In an embodiment, the method comprises: receiving a transverse ultrasound image of a portion of the spine; extracting features of the portion of the spine from the image based on a distinct pattern associated with the anatomical feature of the spine; identifying a midline of the portion of the spine in the image; extracting midline features using pixel intensity values of the image; and identifying, based on a combination of the extracted features of the portion of the spine and the extracted midline features, the anatomical feature in the image. In another embodiment, the method comprises: receiving a paramedian sagittal ultrasound image of a portion of the spine; identifying morphological features of the image; and determining if the portion of the spine includes a sacrum using a Support Vector Machine classifier.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G06T 7/66 - Analysis of geometric attributes of image moments or centre of gravity
• G06V 10/10 - Image acquisition
• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• A61B 17/34 - TrocarsPuncturing needles

Abstract

There is provided an anti-angiogenic agent comprising: a multi-block copolymer in the form of one or more micelles, wherein the copolymer comprises a first poly (alkylene glycol) block, a second poly (alkylene glycol) block and a polyester block. There is also provided a method of preparing said anti-angiogenic agent and medical uses of said anti-angiogenic agent.

IPC Classes  ?

• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• C08G 18/48 - Polyethers
• A61P 27/02 - Ophthalmic agents